Skip to main content
Full access
Influential Publications
Published Online: 14 July 2023

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline

Abstract

Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for Psychedelic Studies (MAPS) obtained Breakthrough Therapy Designation (BTD) from the FDA for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treatment of PTSD on the basis of pooled analyses showing a large effect size for this treatment. This review covers data supporting BTD. In this treatment, MDMA is administered with psychotherapy in up to three monthly 8-h sessions. Participants are prepared for these sessions beforehand, and process material arising from the sessions in follow-up integrative psychotherapy sessions. Comparing data used for the approval of paroxetine and sertraline and pooled data from Phase 2 studies, MAPS demonstrated that MDMA-assisted psychotherapy constitutes a substantial improvement over available pharmacotherapies in terms of safety and efficacy. Studies of MDMA-assisted psychotherapy had lower dropout rates compared to sertraline and paroxetine trials. As MDMA is only administered under direct observation during a limited number of sessions, there is little chance of diversion, accidental or intentional overdose, or withdrawal symptoms upon discontinuation. BTD status has expedited the development of MAPS phase 3 trials occurring worldwide, leading up to a planned submission seeking FDA approval in 2021.
Appeared originally in Front Psychiatry 2019; 10:650

Formats available

You can view the full content in the following formats:

Information & Authors

Information

Published In

History

Published in print: Summer 2023
Published online: 14 July 2023

Keywords

  1. methylenedioxymethamphetamine
  2. posttraumatic stress disorder
  3. breakthrough therapy
  4. sertraline
  5. paroxetine
  6. anxiety

Authors

Details

Allison A. Feduccia
Department of Research Development and Regulatory Affairs, MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Feduccia, Jerome). Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, United States (Yazar-Klosinski, Doblin). MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Emerson). Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States (Mithoefer).
Lisa Jerome [email protected]
Department of Research Development and Regulatory Affairs, MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Feduccia, Jerome). Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, United States (Yazar-Klosinski, Doblin). MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Emerson). Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States (Mithoefer).
Berra Yazar-Klosinski
Department of Research Development and Regulatory Affairs, MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Feduccia, Jerome). Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, United States (Yazar-Klosinski, Doblin). MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Emerson). Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States (Mithoefer).
Amy Emerson
Department of Research Development and Regulatory Affairs, MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Feduccia, Jerome). Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, United States (Yazar-Klosinski, Doblin). MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Emerson). Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States (Mithoefer).
Michael C. Mithoefer
Department of Research Development and Regulatory Affairs, MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Feduccia, Jerome). Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, United States (Yazar-Klosinski, Doblin). MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Emerson). Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States (Mithoefer).
Rick Doblin
Department of Research Development and Regulatory Affairs, MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Feduccia, Jerome). Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, United States (Yazar-Klosinski, Doblin). MAPS Public Benefit Corporation, Santa Cruz, CA, United States (Emerson). Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States (Mithoefer).

Notes

Correspondence: Lisa Jerome [email protected]

Competing Interests

Conflict of Interest Statement: AF received salary support for full time employment with MAPS PBC. LJ received salary support for full time employment with MAPS PBC. BY-K received salary support for full time employment with MAPS. AE received salary support for full time employment with MAPS PBC. MM received salary support from MAPS PBC as a clinical investigator and clinical trial medical monitor as well as for training and supervision of research psychotherapists. RD received salary support for full time employment with MAPS.
The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c) (3) nonprofit organization, provided the MDMA and fully funded this study. MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of MAPS, was the trial organizer. MAPS and MAPS PBC assisted with study design; monitoring of study data; analysis, management, and interpretation of data; preparation, review, and approval of manuscript; and decision to submit the manuscript for publication. The funder had no role in the collection of data or conduct of the study.

Funding Information

Edited by: Felix Müller, University Psychiatric Clinic Basel, Switzerland
Reviewed by: Tomislav Majic, Charité–Universitätsmedizin Berlin, Germany; Katrin H. Preller, University of Zurich, Switzerland
Specialty section: This article was submitted to Psychopharmacology, a section of the journal Frontiers in Psychiatry
Author Contributions: Concept and review design: LJ, AF, AE, BY-K, RD, and MM. Acquisition, analysis, or interpretation of data: LJ, AF, AE, BY-K, RD, and MM. Drafting of the manuscript: LJ, AF, AE, BY-K, RD, and MM. Critical revision of the manuscript for important intellectual content: LJ, AF, AE, BY-K, RD, and MM. Obtained funding: RD.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Focus

PPV Articles - Focus

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share